26 completed, 1 available, 1 unknown. 9 Phase 2, 8 Phase 3, 6 Phase 4, 5 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 3 | 8 | Completed 8 |
| Phase 4 | 6 | Completed 5, Unknown 1 |
| Phase 1 | 5 | Completed 5 |
| Early Phase 1 | 1 | Completed 1 |
Follow burosumab: new trials by email Literature Review of burosumab trials Research Report on burosumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia Burosumab - Fibrous Dysplasia Of Bone | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 12 | 2022-12-07 | 2026-02-02 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO KRN23 - Tumor-Induced Osteomalacia (TIO) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 9 | 2022-09-07 | 2024-07-09 |
| A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth Burosumab - X-Linked Hypophosphatemia | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 25 | 2021-11-24 | 2026-07-13 | |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH KRN23 - X-linked Hypophosphatemia (XLH) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 28 | 2021-11-01 | 2024-07-09 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH KRN23 - X-linked Hypophosphatemia (XLH) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 18 | 2021-09-28 | 2024-07-09 |
| Anti-FGF23 (Burosumab) in Adult Patients With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Wuerzburg University Hospital | 36 | 2021-01-07 | 2023-05-03 |
| A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS) Crysvita (burosumab-twza) Treatment - Epidermal Nevus Syndrome | Phase 4 | Completed | University of Alabama at Birmingham | 1 | 2020-07-31 | 2022-10-07 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| Examining the Effect of Burosumab on Muscle Function Burosumab Injection [Crysvita] - X-linked Hypophosphatemia | Phase 4 | Completed | Yale University | 10 | 2019-11-13 | 2023-08-24 |
| Burosumab for CSHS Burosumab - Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome | Early Phase 1 | Completed | Laura Tosi | 1 | 2019-07-01 | 2026-07-30 |
| Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 35 | 2019-03-07 | 2022-05-20 |
| Burosumab in Children and Adolescents With X-linked Hypophosphatemia Burosumab Injection - Rare Diseases, X-linked Hypophosphatemia | Phase 4 | Unknown | Bicetre Hospital | 57 | 2018-03-18 | 2020-06-05 |
| Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets Burosumab - Hypophosphatemia, Hypophosphatemic Rickets | Phase 3 | Completed | Redwood Dermatology Sciences | 1 | 2018-01-31 | 2020-01-18 |
| A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia KRN23 - XLH | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 27 | 2018-01-09 | 2022-09-06 |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia KRN23 - X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 16 | 2017-07-06 | 2022-09-06 |
| Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH burosumab, Oral Phosphate Supplement, active vitamin D - X-Linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 61 | 2016-09-08 | 2024-08-29 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Burosumab - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 13 | 2016-05-05 | 2024-05-06 |
| A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome KRN23 - Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 14 | 2016-04-01 | 2022-09-06 |
| Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 14 | 2015-12-23 | 2024-06-18 |
| Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) burosumab, Placebo - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 134 | 2015-10-22 | 2024-06-18 |
Showing 20 of 28. Sign in to see all of them.
Familial Hypophosphatemic Rickets (20) · Nevus, Sebaceous of Jadassohn (4) · Oncogenic osteomalacia (4) · Osteomalacia (3) · Bone Diseases, Metabolic (1) · Chronic Pain (1) · Fibrous Dysplasia of Bone (1) · Fibrous Dysplasia, Polyostotic (1) · Hyperparathyroidism (1) · Hypophosphatemia (1) · Rare Diseases (1) · Rickets (1) · Rickets, Hypophosphatemic (1)
Kyowa Kirin Co., Ltd. (11) · Kyowa Kirin, Inc. (7) · Kyowa Kirin Pharmaceutical Development Ltd (3) · Bicetre Hospital (1) · Laura Tosi (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Redwood Dermatology Sciences (1) · University of Alabama at Birmingham (1) · Wuerzburg University Hospital (1) · Yale University (1)
United States (15) · France (7) · Japan (7) · South Korea (6) · United Kingdom (6) · Canada (4) · China (3) · Italy (3) · Germany (2) · Ireland (2) · Netherlands (2) · Spain (2) · Sweden (2) · Australia (1) · Austria (1)
Amy Zhang, PhD (2) · Alison M Boyce, M.D. (1) · Hussein Abdul-Latif, MD (1) · Jeffrey Sugarman, MD PhD (1) · Karl L Insogna, M.D. (1) · Laura Tosi, MD (1) · Lothar Seefried, MD (1) · Peter Kamenicky (1) · Thomas O. Carpenter, M.D. (1)
PMID 39151033, PMID 32721016, PMID 25919461, PMID 36719566, PMID 36854566, PMID 24569459, PMID 26073451, PMID 29791829, PMID 29947083, PMID 30638856, PMID 31104833, PMID 31165191, PMID 33484279, PMID 34548383, PMID 34636899, PMID 34660853, PMID 35533340, PMID 35775373, PMID 35899095, PMID 35927518, PMID 36072994, PMID 37084401, PMID 41634723, PMID 41860923, PMID 42044650
2014 (1)